Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings

Stada Enjoys 8% Top Line Growth In 2021 But Adjusted EBITDA Dips By 1%

Executive Summary

Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.

You may also be interested in...



Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars

Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.

Stada's Sales Grow Double Digits In 2021

Stada strengthened its position as Europe's fourth-largest OTC player in 2021 as sales at its Consumer Healthcare business jumped by 15%.

Stada Steps In To Secure German Tamoxifen Supply

Stada says it is taking action to address current disruptions to the supply of tamoxifen in Germany, with the firm’s Aliud Pharma subsidiary bringing in supplies from Stada’s EG business in Italy.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel